Interstitial Lung Disease
Conditions
Keywords
Interstitial lung disease
Brief summary
The purpose of this study is investigating the clinical course, treatment course, and prognosis of patients with interstitial lung disease.
Detailed description
Interstitial lung disease refers to pulmonary disease that occurs in the interstitium of the lung. It can be broadly classified into lung disease secondary to the cause of systemic disease or drug, and lung disease whose cause is unknown, and the latter is known as idiopathic interstitial pneumonia. Idiopathic interstitial pneumonia is a lung disease showing various aspects of inflammatory response and fibrosis reaction, and the cause of the onset is not accurately known yet, also there is no effective treatment. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis, progresses very slowly, but sometimes acute exacerbation without any obvious cause leads to death, rapidly. Therefore, it is important to collect data prospectively for changes in clinical features, pulmonary function, imaging findings, and quality of life of these patients. A prospective study of idiopathic interstitial pneumonia will provide important information on the clinical characteristics and admission history of patients with idiopathic interstitial pneumonia, and the idiopathic interstitial pneumonia registry system will serve as the basis for further prospective observational studies. The aim of this study is to establish the registry of patients with interstitial lung disease and to prospectively review the clinical features and progression of the patients.
Interventions
OTHERmonitoring changes in clinical symptoms, pulmonary function, and chest radiography
For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Inclusion criteria
* Patients older than 20 years diagnosed with interstitial lung disease * Diagnostic criteria for interstitial lung disease. If one of the following is met: 1. clinical suspicion of idiopathic pulmonary fibrosis (IPF); Characteristic chest CT findings with honeycomb cysts and fibrosis and reasonable clinical signs 2. suspected interstitial pneumonia, or confirmed by biopsy with no evidence of infection : IPF, Non-specific interstitial pneumonia(NSIP), Cryptogenic organizing pneumonia(COP), unclassified fibrosis 3. interstitial lung disease suspects with underlying rheumatic disease
Exclusion criteria
* No specific criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| St George's Respiratory Questionnaire(SGRQ) | at baseline, every 1 year through study completion for 10 years | monitoring changes in clinical symptoms |
| modified Medical Research Council (mMRC) dyspnea scale | at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years | monitoring changes in clinical symptoms |
| Borg dyspnea scale | at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years | monitoring changes in clinical symptoms |
| Hospital anxiety and depression score(HADS) | at baseline, every 1 year through study completion for 10 years | monitoring changes in clinical symptoms |
| chest X-ray | at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years | monitoring changes in chest radiography |
| Chest CT | at baseline, every 1 year through study completion for 10 years | monitoring changes in chest radiography |
| Paranasal sinus X-ray(PNS series) | at baseline | baseline PNS X-ray |
| Electrocardiogram(ECG) | at baseline | baseline ECG |
| Pulmonary function test with bronchodilator response test(PFT+BDR) | at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years | monitoring changes in lung function |
| Diffusing capacity of the lungs for carbon monoxide(DLCO) | at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years | monitoring changes in lung function |
| total lung capacity(TLC) | at baseline | monitoring changes in lung function |
| Bronchoscopic alveolar lavage(BAL) | at baseline | for diagnostic purposes if necessary |
| Video-assisted thoracoscopic surgery(VATS) lung biopsy | at baseline | for diagnostic purposes if necessary |
| echocardiography | at baseline | additionally tested at acute exacerbation |
| arterial blood gas analysis(ABGA) | at baseline | additionally tested at acute exacerbation |
Countries
South Korea
Contacts
Primary ContactChoi Sun Mi
Backup ContactPARK HEEMOON
Outcome results
None listed